3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
32
Phase EARLY_PHASE1
2
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Lymphoma
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Rectal Neoplasms
1
Pain
1
Neoplasms
1
Mucositis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphedema
1
Glioma
1
Fallopian Tube Neoplasms
1
Carcinoma in Situ
1
Brenner Tumor
1
Breast Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Abnormalities, Radiation-Induced
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Methods
×
Clear all
NCT01272024
2016-06-15
TEAMS
Yale University
Phase 3
Completed
146 enrolled